Navigation Links
Aratana Therapeutics Reports Second Quarter 2013 Financial Results
Date:8/12/2013

KANSAS CITY, Kan. and BOSTON, Aug. 12, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX) today announced its financial results for the second quarter of 2013, product development updates and the continued build-out of its pipeline.

For the quarter ended June 30, 2013, the Company reported a net loss of $4.2 million, or $(4.62) per share, compared with a net loss of $3.1 million, or $(10.21) per share for the quarter ended June 30, 2012. For the six months ended June 30, 2013, the Company reported a net loss of $8.3 million, or $(9.35) per share, compared with a net loss of $5.8 million, or $(19.15) per share for the six months ended June 30, 2012.

As of June 30, 2013, the Company had a total of approximately $20.2 million in cash, cash equivalents and marketable securities.
This number reflects the prepayment in June of $2.7 million of expenses related to the Company's initial public offering. In July, the Company completed the initial public offering which, together with the exercise of the underwriters' overallotment, provided $34.2 million in net proceeds. The Company's total cash and cash equivalents post-IPO was approximately $57.1 million.

"We are aggressively moving forward following our recent IPO with a sharp focus on our clinical programs and expanding our product pipeline," said Dr. Steven St. Peter, President and CEO of Aratana Therapeutics.  "We are pleased to share details on our progress and plans for the future."

Development Programs and Upcoming Milestones

  • AT-001 Dog: Completed enrollment in dose-ranging field study; results expected in November 2013; anticipate U.S. approval in 2016
  • AT-001 Cat: Anticipate initiating additional proof of concept study this month; results expected in November 2013
  • AT-002 Dog: Continuing discussion with the Center for Veterinary Medicine (CVM) to gain concur
    '/>"/>

  • SOURCE Aratana Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Aratana to Participate in Leerink Swanns November Management Access Days
    2. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
    3. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
    4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
    5. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
    6. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
    7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
    (Date:1/22/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the ... therapies for cardiovascular disease and overall health is pleased to ... 2014 and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share ...
    (Date:1/22/2015)... 22, 2015  Bio-Techne Corporation (NASDAQ: TECH ) ... member of the new Simple Plex platform through its ... represents the re-branding of the previously acquired CyPlex instrument ... is a transformative immunoassay technology which integrates an innovatively ...
    Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
    ... 31 A recent outbreak of MRSA,(Methicillin- resistant ... should cause organizations and facilities nationwide to,reevaluate and ... is resistant to common antibiotics. It manifests its,symptoms ... other pus-filled,lesions. Superbug infections prior to 2007 were ...
    ... United,Therapeutics Corporation (Nasdaq: UTHR ) and its ... will release the results of their,TRIUMPH-1 Phase 3 ... pulmonary arterial hypertension (PAH) before market open on ... its previously scheduled conference,call on November 1, 2007, ...
    Cached Medicine Technology:'Superbug' Outbreak Calls for Immediate Increased Attention on Infection Control 2Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007 2
    (Date:1/22/2015)... (PRWEB) January 22, 2015 The City of West ... 10 a.m., to commemorate the 42nd anniversary of the Supreme Court ... , “It’s been 42 years since the Roe vs. Wade decision ... still as present as ever,” said City of West Hollywood Councilmember ...
    (Date:1/22/2015)... (PRWEB) January 23, 2015 VogueQueen is a ... affordable prices and many designers are thrilled to have it ... business announces its new collection of prom dresses for the ... to drive the strategic vision and he focuses on continuing ...
    (Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
    (Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
    (Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
    Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
    ... University of Texas at Austin,s new Health Information Technology ... the Professional University Resources and Education for Health Information ... from the U.S. Department of Health and Human Services ... Technology. The program graduated its first class of ...
    ... of the most spectacular migrations on Earth is that of ... Acknowledged as one of the wonders of the natural world, ... five-kilometre breeding migration. Now, scientists have discovered the key to ... a team led by the late Professor Steve Morris from ...
    ... with bacterial pneumonia decreased by a fifth in the two ... disease, according to a new study published today in the ... illness caused by Streptococcus pneumoniae bacteria that mostly ... one in ten deaths in the under-fives is caused by ...
    ... HealthDay Reporter , THURSDAY, Aug. 26 (HealthDay News) ... as likely as their religious counterparts to make medical choices ... a new British study reveals. "The religious beliefs of ... concludes study author Clive Seale, a professor of medical sociology ...
    ... By Dennis Thompson HealthDay Reporter , ... a chronic illness that challenges you every single day. ... sometimes suffer from surprising decreases in energy. You take ... procedures to keep the illness from progressing. The ...
    ... Compliance with practice guideline-recommended treatment for cirrhosis is ... hemorrhage (EVH; bleeding), according to a new study ... official journal of the American Gastroenterological Association (AGA) ... liver is permanently scarred or injured. "Esophageal ...
    Cached Medicine News:Health News:Health IT program at the University of Texas at Austin receives $2.7 million in federal funding 2Health News:Health IT program at the University of Texas at Austin receives $2.7 million in federal funding 3Health News:Scientists discover key to Christmas Island's red crab migration 2Health News:Vaccine has cut child cases of bacterial pneumonia, says study 2Health News:Vaccine has cut child cases of bacterial pneumonia, says study 3Health News:Doctors' Religious Beliefs Can Color Their Care of Terminally Ill 2Health News:Doctors' Religious Beliefs Can Color Their Care of Terminally Ill 3Health News:Doctors' Religious Beliefs Can Color Their Care of Terminally Ill 4Health News:Does Hope Have a Dark Side? 2Health News:Does Hope Have a Dark Side? 3Health News:Adherence to practice guidelines may reduce bleeding in cirrhosis patients 2
    Its generous filter placement, MicroPoint design, and reference marks at 10, 50, and 100 ul make this ART tip ideal for many 200 ul pipettors....
    ... microfuge tubes and PCR tubes. Certified ... and DNase-free. Tubes have a positive ... Available in a variety of sizes. ... low binding surface. PCR Tubes are ...
    Designed for the Eppendorf and Pipetman 100 ul pipettors, this tip features MicroPoint design, reference mark at 10 ul and a yellow tip design for the most universal fit....
    Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
    Medicine Products: